Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 303Parkinson Disease 4, Autosomal Dominant Lewy Body 180Melanoma 166Neoplasms 134Squamous Cell Carcinoma of Head and Neck 126Neoplasm Metastasis 99Colorectal Neoplasms 97Carcinoma, Renal Cell 80Triple Negative Breast Neoplasms 75Head and Neck Neoplasms 72Stomach Neoplasms 71Lung Neoplasms 69Breast Neoplasms 60Ovarian Neoplasms 56Carcinoma, Transitional Cell 51Uterine Cervical Neoplasms 44Pancreatic Neoplasms 44Endometrial Neoplasms 44Urinary Bladder Neoplasms 40Esophageal Neoplasms 40Carcinoma, Hepatocellular 37Small Cell Lung Carcinoma 30Cholangiocarcinoma 24Carcinoma 23Prostatic Neoplasms 22Lymphoma 20Carcinoma, Squamous Cell 20Recurrence 17Sarcoma 16Esophageal Squamous Cell Carcinoma 16

Interventions

relacorilant 6Mifepristone 4Corlux 3Osilodrostat 2pembrolizumab 1Dabigatran 1ASP3662 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cushing Syndrome × pembrolizumab × Clear all
NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡